个人简介：国家高层次引进人才青年项目入选者，中山大学中山医学院、人类病毒学研究所教授。2004年获得中国农业大学生物学院生物化学与分子生物学（分子病毒学研究方向）博士学位；博士学习期间到丹麦技术大学国家兽医研究所和德国Friedrich-Loeffler研究所学习一年。2004和2006-2007年，丹麦技术大学国家兽医研究所（Project Researcher & Postdoc）；2005年，加拿大萨斯喀彻温大学疫苗与传染病研究所（Postdoc）；2008-2014，丹麦哥本哈根大学Hvidovre医院传染病与临床研究中心（Postdoc & Senior Investigator）。2014年全职回中山大学中山医学院工作。
长期从事病毒学研究，在丙肝病毒（HCV）的分子生物学、细胞感染模型和抗病毒药物的研究上，取得系列重要研究成果，研究出一套系统的新方法，鉴定出一组关键突变，建立了基因型1，2，3，4，5，6嵌合和全长HCV感染性克隆，开辟了建立HCV细胞感染模型的新途径；利用这些感染性HCV重组病毒，阐明HCV对主要临床药物的浓度依赖性和基因型特异性，以及耐药的分子机制。实验室正进行HCV、登革病毒（DENV）和寨卡病毒（ZIKV）的分子病毒学与病毒逃逸免疫和药物的研究。2020年初，同时开展新冠病毒（SARS-CoV-2）的研究。
主要成果发表在PNAS，EMBO J, Gastroenterology，Hepatology, PLoS Pathogens, Journal of Virology，Frontiers in Microbiology和Virology等病毒学领域重要期刊上；Web of Science统计H-Index=18（7/7/2020）。获得5项美国和欧洲专利，申请2项中国专利。
课题组招聘研究员，副研究员和博士后，欢迎有志从事分子病毒学和抗病毒免疫的同行联系加入研究组。
Yiping Li, Ph.D., Professor of Molecular Virology,?Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University (SYSU), Guangzhou, China. Dr. Li received Ph.D. degree in Biochemistry and Molecular Biology from China Agricultural University, Beijing, China. From 2003 to 2004 and 2006 to 2007, Dr. Li worked as a visiting scholar, project researcher, and postdoctoral researcher in the National Veterinary Institute, Technical University of Denmark (previous Royal Danish Veterinary Institute). In 2005, Dr. Li pursued hepatitis C virus (HCV) research in the Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada. To continue HCV research, in February 2008 Dr. Li joined the Copenhagen Hepatitis C Program (CO-HEP), Hvidovre Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, as a senior investigator. In January 2014, Dr. Li took a professor position in Zhongshan School of Medicine, SYSU.
Dr. Yiping Li’s research interests are primarily in the molecular virology and viral escapes (immunity and antivirals) of Flaviviridae viruses, including HCV, dengue virus (DENV), and Zika virus (ZIKV). Early 2020, SARS-CoV-2 (COVID-19 virus) was also included. Dr. Li has made important contributions in the development of recombinant chimeras and novel full-length infectious culture systems for HCV genotypes 1, 2, 3, 4, 5, and 6. In addition, Dr. Li has developed reverse genetic systems for DENV and ZIKV, and demonstrated novel mechanisms of virus-host interactions and pathogenesis. Dr. Li’s works have led to publications on well-known journals, such as PNAS, The EMBO Journal, Gastroenterology, Hepatology, PLoS Pathogens, Journal of Virology, Frontiers in Microbiology, Virology, etc.. which have earned H-index of 18. Besides, Dr. Li have received 5 US and EU patents (2 Chinese patents submitted).
Positions openings and postgraduates: We are recruiting research associates, postdoc, research assistant and trainees. Candidates who pursue their Master and PhD studies are welcome to contact. Please send your cover letter, CV and applications to lyiping@mail.sysu.edu.cn
?
导????师：博士导师,硕士导师?
学科专业：病毒学/Virology?
主要研究论文（*, 通讯作者；#，共同第一作者。 按发表时间顺序排列） ? ?? ?
Zheng F, Li N, Xu Y, Zhou Y, Li YP*. Adaptive mutations promote hepatitis C virus assembly by accelerating Core translocation to the endoplasmic reticulum. Journal of Biological Chemistry. 2020 Nov 3:jbc.RA120.016010. doi: 10.1074/jbc.RA120.016010. (PubMed)
Zhang J#, Wu Q#, Liu Z#, Wang Q#, Wu J#, Hu Y#, Bai T, Xie T, Huang M, Wu T, Peng D, Huang W, Jin K, Niu L, Guo W, Luo D, Lei D, Wu Z, Li G, Huang R, Lin Y, Xie X, He S, Deng Y, Liu J, Li W, Lu Z, Chen H, Zeng T, Luo Q, Li YP*, Wang Y*, Liu W*, Qu X*. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nature Microbiology. 2020 Nov 16. doi: 10.1038/s41564-020-00824-5. (PubMed)
Li YP*. Antigen glycosylation broadens the immunogenicity of E2 subunit HCV vaccines. Annals of Blood 2020;5:17 doi: 10.21037/aob-19-77. (Invited Editorial Commentary) (AOB)
Li X, Li J, Feng Y, Cai H, Li YP*, Peng T*. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Antiviral Research 2020;177:104734. doi: 10.1016/j.antiviral.2020.104734. PMID: ** (PubMed)
Wu Y, Jin S, Liu Q, Zhang Y, Ma L, Zhao Z, Yang S, Li YP, Cui J*. Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression. Autophagy 2020:1-14. doi: 10.1080/**.2020.**. PMID: ** (PubMed)
Ramirez S, Fernandez-Antunez C, Mikkelsen LS, Pedersen J, Li YP, Bukh J*. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Antimicrobial Agents and Chemotherapy 2020;64(3):e01888-19. doi: 10.1128/AAC.01888-19. PMID: ** (PubMed)
Zhang Z, Rong L, Li YP*. Flaviviridae Viruses and Oxidative Stress: Implications for Viral Pathogenesis. Oxidative Medicine and Cell Longevity 2019 Aug 19;2019:**. doi: 10.1155/2019/**. PMID: ** (PubMed)
Liu T, Tang L, Tang H, Pu J, Gong S, Fang D, Zhang H, Li YP, Zhu X, Wang W, Wu M, Liao Y, Li C*, Zhou H*, Huang X*. Zika Virus Infection Induces Acute Kidney Injury Through Activating NLRP3 Inflammasome Via Suppressing Bcl-2. Frontiers in Immunology 2019;10:192 doi: 10.3389/fimmu.2019.01925. PMID: ** (PubMed)
Yuan G, Rong L, Liu J, Zhang Z, Hu C, Chen M, Ma L, Zhang YY, Li YP, Zhou Y*. Serum?derived hepatitis C virus can infect human glioblastoma cell line SF268 and activate the PI3K?Akt pathway. Molecular Medicine Reports 2019;19(5):4441-4448. doi: 10.3892/mmr.2019.10063. PMID: ** (PubMed)
Chen M, Zheng F，Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP*. Development of an infectious cell culture system for hepatitis C virus genotype 6a clinical isolate using a novel strategy and its sensitivity to direct-acting antivirals. Frontiers in Microbiology 2018 Dec 4;9:2950. doi:10.3389/fmicb.2018.02950. PMID: ** (PubMed).
Wang Y, Chen X, Xie J, Zhou S, Huang Y, Li YP, Li X, Liu C, He J*, Zhang P*. RNA helicase A is an important host factor involved in dengue virus replication. Journal of Virology 2019;93(4). pii: e01306-1 doi: 10.1128/JVI.01306-18. PMID: ** (PubMed)
Zheng Y#, Liu Q#, Wu Y#, Ma L, Zhang Z, Liu T, Jin S, She Y, Li YP*, Cui J*. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis. The EMBO Journal 2018;37(18). pii: e99347. PMID: ** (PubMed)
Chen Y, Liu T, Zhang Z, Chen M, Rong L, Ma L, Yu B, Wu, Zhang P, Zhu X, Huang X, Zhang H, Li YP*. Novel genetically stable infectious clone for a Zika virus clinical isolate and identification of RNA elements essential for virus production. Virus Research. 2018;257:14-24. PMID: ** (PubMed)
Duan X, Anwar MI, Xu Z, Ma L, Yuan G, Chen Y, Liu X, Xia J, Zhou Y, Li YP*. Adaptive Mutation F772S-enhanced p7-NS4A Cooperation Facilitated the Assembly and Release of Hepatitis C Virus and Associated with Enlargement of Lipid Droplets. Emerging Microbes & Infections 2018 Aug 8;7(1):143. PMID: ** (PubMed)
Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J*. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology 2018;522:177-192. PMID: ** (PubMed)
Li J, Feng S, Liu X, Guo M, Chen M, Chen Y, Rong L, Xia J, Zhou Y, Zhong J, Li YP*. Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1). Virology 2018;518:253-263. PMID: ** (PubMed)
Yang JY, Deng XY, Li YS, Ma XC, Feng JX, Yu B, Chen Y, Luo YL, Wang X, Chen ML, Fang ZX, Zheng FX, Li YP, Zhong Q, Kang TB, Song LB, Xu RH, Zeng MS, Chen W, Zhang H, Xie W, Gao S*. Structure of Schlafen13 reveals a new class of tRNA/rRNA- targeting RNase engaged in translational control. Nature Communications 2018;9(1):1165. PMID: ** (PubMed)
Pham LV, Ramirez S, Gottwein JM, Fahn?e U, Li YP, Pedersen J, Bukh J*. HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology **(8):2194-2208.e12. PMID: ** (PubMed)
Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T*. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Research 2017;148:5-14. PMID: ** (PubMed)
Huang LH, Xu MY, Li HJ, Li JQ, Chen YX, Ma WZ, Li YP, Xu J*, Yang DP*, Lan WJ*. Amino Acid-Directed Strategy for Inducing the Marine-Derived Fungus Scedosporium apiospermum F41?1 to Maximize Alkaloid Diversity. Organic Letters 2017;19:4888-4891. PMID:** (PubMed)
Yuan G, Liu J, Hu C, Huang H, Qi M, Wu T, Liang W, Li YP, Zhang YY, Zhou Y*. Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Guangzhou, China: Predominance of Genotype 1b and Increasing Incidence of Genotype 6a. Cellular Physiology and Biochemistry 2017;43(2):775-787. PMID:** (PubMed)
Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W*. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. Scientific Reports 2017;7(1):3976. PMID: ** (PubMed)
Fang S, Su J, Liang B, Li X, Li Y, Jiang J, Huang J, Zhou B, Ning C, Li J, Ho W, Li YP, Chen H, Liang H, Ye L*. Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Scientific Reports 2017;7:44039. PMID:** (PubMed)
Li X, Li Y, Fang S, Su J, Jiang J, Liang B, Huang J, Zhou B, Zang N, Ho W, Li J, Li YP, Chen H, Ye L, Liang H*. Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-λ1 contributes to its anti-HCV activity in human hepatoma cells. Antiviral Research 2017;140:83-94. PMID:** (PubMed)
Pham LV, Ramirez S, Carlsen TH, Li YP, Gottwein JM, Bukh J*. Efficient hepatitis C virus genotype 1b Core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors. Antimicrobial Agents and Chemotherapy 2017 24;61(6). pii: e00037-17, PMID:** (PubMed)
Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F, Fan J, Li X, Jin Q, Zhong J, Li YP, Yang W*. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Scientific Reports 2016;6:25224. PMID:** (PubMed)
Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM*. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrobial Agents and Chemotherapy 2016;60(6):3563-78. PMID:** (PubMed)
Li YP#, Van Pham L#, Uzcategui N, Bukh J. Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir. Journal of General Virology 2016;97(6):1381-94. PMID:** (PubMed)
Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM*. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrobial Agents and Chemotherapy 2015;59(12):7426-36. PMID:** (PubMed)
Li YP#, Ramirez S#, Mikkelsen L, Bukh J*. Efficient Infectious Cell Culture Systems of the Hepatitis C Virus (HCV) Prototype Strains HCV-1 and H77. Journal of Virology 2015;89(1):811-23. PMID: ** (PubMed)
Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J*. Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors. Gastroenterology?2014;146(3):812-821. PMID:** (PubMed)
Ramirez R, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J*. Highly efficient infectious Cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors. Hepatology 2014;59(2):395-407. PMID:** (PubMed)
Scheel TKH#, Galli1 A#, Li YP, Mikkelsen LS, Gottwein JM, Bukh J*. Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. PLoS Pathogens 2013;9(3):e**. PMID:** (PubMed)
Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TKH, Serre S, Mikkelsen L, Bukh J*. Combination treatment with HCV protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a and 3a virus. Antimicrobial Agents and Chemotherapy 2013;57(3):1291-303). PMID:**. (PubMed)
Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J*. Highly efficient full-length hepatitisC virus genotype 1 (strain TN) infectious culture system. Proceedings of the National Academy of Sciences of the United States of America 2012;109(48):19757-19762. PMID:** (PubMed)
Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J*. Robust full-length HCV genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences of the United States of America 2012;109(18):E1101-1110. PMID:** (PubMed)
Li YP, Ramirez S, Gottwein JM, Bukh J*. Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. Virology 2011;421(2):222-2 PMID:** (PubMed)
Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J*. MicroRNA-122 antagonism against hepatitis C virus genotype 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5'UTR. Proceedings of the National Academy of Sciences of the United States of America 2011;108(12):4991-4996. PMID:** (PubMed)
Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J*. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. Journal of Virology 2011;85(6):2891-2906. PMID:** (PubMed)
Li YP*, Vegge CS, Brondsted L, Madsen M, Ingmer H, Bang DD. Campylobacter jejuni induces an anti-inflammatory response in human intestinal epithelial cells through activation of phosphatidylinositol 3-kinase/Akt pathway. Veterinary Microbiology 2011;148(1):75-83. PMID:** (PubMed)
Gottwein JM#, Scheel TK#, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J*. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. Journal of Virology 2010;84(10):5277-5293. PMID:** (PubMed)
Vegge CS, Brondsted L, Li YP, Bang DD, Ingmer H*. Energy taxis drives Campylobacter jejuni toward the most favorable conditions for growth. Applied and Environmental Microbiology 2009;75(16):5308-5314. PMID:** (PubMed)
Li YP*, Ingmer H, Madsen M, Bang DD. Cytokine responses in primary chicken embryo intestinal cells infected with Campylobacter jejuni strains of human and chicken origin and the expression of bacterial virulence-associated genes. BMC Microbiology 2008;8:107. PMID:** (PubMed)
Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, Babiuk LA, Liu Q*. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. Journal of General Virology 2008;89(Pt 5):1225-1230. PMID:** (PubMed)
Oem JK, Jackel-Cram C, Li YP, Kang HN, Zhou Y, Babiuk LA, Liu Q*. Hepatitis C virus non-structural protein-2 activates CXCL-8 transcription through NF-kappaB. Archives of Virology 2008;153(2):293-301. PMID:** (PubMed)
Li YP*, Handberg KJ, Juul-Madsen HR, Zhang MF, Jorgensen PH. Transcriptional profiles of chicken embryo cell cultures following infection with infectious bursal disease virus. Archives of Virology 2007;152(3):463-478. PMID:** (PubMed)
Li YP, Handberg KJ*, Kabell S, Kusk M, Zhang MF, Jorgensen PH. Relative quantification and detection of different types of infectious bursal disease virus in bursa of Fabricius and cloacal swabs using real time RT-PCR SYBR green technology. Research in Veterinary Sciences 2007;82(1):126-133. PMID:** (PubMed)
Li YP, Kang HN, Babiuk LA, Liu Q*. Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World Journal of Gastroenterology 2006;12(44):7126-7135. PMID:** (PubMed)
Bang DD*, Li YP, Nielsen SN, Madsen M. Pathogenesis properties of Campylobacter jejuni isolates obtained from different sources originating from four different EU countries. International Journal of Infectious Diseases 2006;10 (Suppl.): 217.
Li YP, Bang DD, Handberg KJ*, Jorgensen PH, Zhang MF. Evaluation of the suitability of six host genes as internal control in real-time RT-PCR assays in chicken embryo cell cultures infected with infectious bursal disease virus. Veterinary Microbiology 2005;110(3-4):155-165. PMID:** (PubMed)
Kabell S*, Handberg KJ, Li YP, Kusk M, Bisgaard M. Detection of vvIBDV in vaccinated SPF chickens. Acta Veterinaria Scandinavica 2005;46(4):219-227. PMID:** (PubMed)
Li YP, Zhang MF*. Rapid pathotyping of Newcastle disease virus from allantoic fluid and organs of experimentally infected chickens using two novel probes. Archives of Virology 2004;149(6):1231-1243. PMID:** (PubMed).
?
学术论著与教材：??
1. 译著.Book chapters.
1). 李义平，郑福祥，徐占雪, 病毒感染与人类肿瘤-从基础科学到临床预防（第 九章），ISBN 978-7-03-047942-6，p146-p155，北京:东黄城根北街16号, 科学出版社。（全书三个主译之一）。
2). 李义平，徐占雪，郑福祥，病毒感染与人类肿瘤-从基础科学到临床预防（第10章），ISBN 978-7-03-047942-6，p161-p173，北京:东黄城根北街16号, 科学出版社。（全书三个主译之一）。
2. 特邀专家论坛.综述:
1). 李义平，HCV细胞感染模型研究进展及其在药物研究中的应用，临床肝胆病杂志，2015, 31(11); 1825-1830.
?
基金与奖励:?
2020:?欧盟地平线2020?新冠病毒研究项目（EU Horison 2020, H2020-SC1-PHE-CORONAVIRUS-2020）
2020: 国家自然科学基金
2020: 国家重研发计划项目"生物安全关键技术"专项
2017: 广东省粤港澳科技合作项目
2016:?广东省科学技术发展基金
2015: 国家自然科学基金
2015: 国家重点基础研究发展计划（973计划）
2014：广东省自然科学基金
2014.01：入选国家高层次引进人才青年项目
2014：丹麦Novo Nordisk研究基金?
2012-2015：丹麦国家科学技术和创新研究基金-医学科学独立研究基金?
2012-2014：丹麦Lundbeck 研究基金?
2012：丹麦Novo Nordisk研究基金?
2011-2014：丹麦国家科学技术和创新研究基金-医学科学独立研究基金?
2006：英国The Houghton Trust基金
2003：英国The Houghton Trust基金?
?学术兼职：?
Danish Society?for Virology
广东省转化医学学会
病毒学报编委